AGN News and Press, Allergan plc From 01/27/20

Some unlikely good Samaritans are going out of their way to help AbbVie (NYSE: ABBV) and Allergan   (NYSE: AGN) complete the $63 billion merger deal the giant drugmakers announced last June. To appease antitrust regulators,  AstraZeneca   (NYSE: AZN) will take back control ...

About AbbVie Source: AbbVie Presentation AbbVie: Investment Thesis In the 5 months since the July 18, 2019 date of publication of my article, " Sell Celgene, Buy Bristol-Myers Ahead Of Proposed Merger ", the Bristol-Myers share price has increased by 46% from $44.05 to $64.16 today....

Evolus (NASDAQ: EOLS ) is up  3%  premarket on light volume in reaction to its announcement of results from a Korea-based Phase 3 head-to-head study comparing Jeuveau (prabotulinumtoxinA-xvfs) to Allergan's (NYSE: AGN ) Botox (onabotulinumtoxinA) for the treatment of frown lines....

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Traders across the globe are starting the week in risk-off mode amid growing concerns over the potential economic damage from the...

AbbVie (NYSE: ABBV ) and Allergan (NYSE: AGN ) announce that latter has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase). These agreements are in conjunction with the ongoing merger process of both the companies. More news on: AbbVi...

Looking to expand in medical nutrition, Nestle ( OTCPK:NSRGY ) is buying Allergan's (NYSE: AGN ) Zenpep, which had sales of $237M in 2018. More news on: Nestle S.A. ADR, Allergan plc, Nestle S.A., Healthcare stocks news, Read more ...

NORTH CHICAGO, Ill. and DUBLIN , Jan. 27, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan has entered into definitive agreements to divest b...

Allergan 's (NYSE: AGN) days as a standalone company are numbered. We don't know exactly when AbbVie 's (NYSE: ABBV) pending acquisition of Allergan will close, but it should happen sometime in the first quarter of 2020. This deal certainly lit a fire beneath Allergan stock, with the drug...

Shareholders of drugmaker Mylan (NASDAQ: MYL) are off to a good start this year, with an 8.4% gain after last year's 27% loss. The market may be thinking of the company's planned combination with Pfizer 's Upjohn business, which focuses on off-patent branded drugs and generics. The dea...

AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are two of the largest pharmaceutical companies in the world. However, big doesn't mean buy, and both of these juggernauts currently face headwinds that may scare many investors away. AbbVie is dealing with Humira's declining inte...